John P. O'Bryan

Title
InstitutionMedical University of South Carolina
DepartmentCell and Molecular Pharmacology and Experimental Therapeutics
AddressP.O. Box MSC 955
HO712E
Hollings Cancer Center - 86 Jonathan Lucas St.
Phone843-792-8393
Fax843-792-2475
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sofi MH, Tian L, Schutt S, Khan I, Choi HJ, Wu Y, Bastian D, Ticer T, Kassir MF, Atilgan FC, Kim J, Sui X, Zivkovic A, Mehrotra S, O'Bryan JP, Stark H, Martin PJ, Ogretmen B, Yu XZ. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia. 2022 07; 36(7):1907-1915. PMID: 35513703.
      Citations:    
    2. Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322. PMID: 35139380.
      Citations:    
    3. O'Bryan JP, Piazza GA. Preface. Adv Cancer Res. 2022; 153:xiii-xiv. PMID: 35101237.
      Citations:    
    4. Treffy RW, Rajan SG, Jiang X, Nacke LM, Malkana UA, Naiche LA, Bergey DE, Santana D, Rajagopalan V, Kitajewski JK, O'Bryan JP, Saxena A. Neuroblastoma differentiation in vivo excludes cranial tumors. Dev Cell. 2021 10 11; 56(19):2752-2764.e6. PMID: 34610330.
      Citations:    
    5. Whaby M, Khan I, O'Bryan JP. Targeting the "undruggable" RAS with biologics. Adv Cancer Res. 2022; 153:237-266. PMID: 35101232.
      Citations:    
    6. Ash D, Sudhahar V, Youn SW, Okur MN, Das A, O'Bryan JP, McMenamin M, Hou Y, Kaplan JH, Fukai T, Ushio-Fukai M. The P-type ATPase transporter ATP7A promotes angiogenesis by limiting autophagic degradation of VEGFR2. Nat Commun. 2021 05 25; 12(1):3091. PMID: 34035268.
      Citations:    
    7. Teng KW, Tsai ST, Hattori T, Fedele C, Koide A, Yang C, Hou X, Zhang Y, Neel BG, O'Bryan JP, Koide S. Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nat Commun. 2021 05 11; 12(1):2656. PMID: 33976200.
      Citations:    
    8. Khan I, MarElia-Bennet C, Lefler J, Zuberi M, Denbaum E, Koide A, Connor DM, Broome AM, Pécot T, Timmers C, Ostrowski MC, Koide S, O'Bryan JP. Targeting the KRAS a4-a5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases. 2021 May 05; 1-14. PMID: 33949915.
      Citations:    
    9. Khan I, O'Bryan JP. Probing RAS Function with Monobodies. Methods Mol Biol. 2021; 2262:281-302. PMID: 33977484.
      Citations:    
    10. Zuberi M, Khan I, O'Bryan JP. Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020 10 30; 48(5):1831-1841. PMID: 32869838.
      Citations:    
    11. Sudhahar V, Okur MN, O'Bryan JP, Minshall RD, Fulton D, Ushio-Fukai M, Fukai T. Caveolin-1 stabilizes ATP7A, a copper transporter for extracellular SOD, in vascular tissue to maintain endothelial function. Am J Physiol Cell Physiol. 2020 11 01; 319(5):C933-C944. PMID: 32936699.
      Citations:    
    12. Rhett JM, Khan I, O'Bryan JP. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020; 148:69-146. PMID: 32723567.
      Citations:    
    13. Khan I, Rhett JM, O'Bryan JP. Therapeutic targeting of RAS: New hope for drugging the "undruggable". Biochim Biophys Acta Mol Cell Res. 2020 02; 1867(2):118570. PMID: 31678118.
      Citations:    
    14. Khan I, Spencer-Smith R, O'Bryan JP. Correction: Targeting the a4-a5 dimerization interface of K-RAS inhibits tumor formation in vivo. Oncogene. 2019 May; 38(22):4426. PMID: 30710144.
      Citations:    
    15. Khan I, Spencer-Smith R, O'Bryan JP. Targeting the a4-a5 dimerization interface of K-RAS inhibits tumor formation in vivo. Oncogene. 2019 04; 38(16):2984-2993. PMID: 30573767.
      Citations:    
    16. Sudhahar V, Okur MN, Bagi Z, O'Bryan JP, Hay N, Makino A, Patel VS, Phillips SA, Stepp D, Ushio-Fukai M, Fukai T. Akt2 (Protein Kinase B Beta) Stabilizes ATP7A, a Copper Transporter for Extracellular Superoxide Dismutase, in Vascular Smooth Muscle: Novel Mechanism to Limit Endothelial Dysfunction in Type 2 Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):529-541. PMID: 29301787.
      Citations:    
    17. Spencer-Smith R, O'Bryan JP. Direct inhibition of RAS: Quest for the Holy Grail? Semin Cancer Biol. 2019 02; 54:138-148. PMID: 29248537.
      Citations:    
    18. Harris J, Herrero-Garcia E, Russo A, Kajdacsy-Balla A, O'Bryan JP, Chiu B. Silencing Intersectin 1 Slows Orthotopic Neuroblastoma Growth in Mice. J Pediatr Hematol Oncol. 2017 11; 39(8):e413-e418. PMID: 28787396.
      Citations:    
    19. Spencer-Smith R, Koide A, Zhou Y, Eguchi RR, Sha F, Gajwani P, Santana D, Gupta A, Jacobs M, Herrero-Garcia E, Cobbert J, Lavoie H, Smith M, Rajakulendran T, Dowdell E, Okur MN, Dementieva I, Sicheri F, Therrien M, Hancock JF, Ikura M, Koide S, O'Bryan JP. Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol. 2017 Jan; 13(1):62-68. PMID: 27820802.
      Citations:    
    20. Herrero-Garcia E, O'Bryan JP. Intersectin scaffold proteins and their role in cell signaling and endocytosis. Biochim Biophys Acta Mol Cell Res. 2017 Jan; 1864(1):23-30. PMID: 27746143.
      Citations:    
    21. Burmeister BT, Wang L, Gold MG, Skidgel RA, O'Bryan JP, Carnegie GK. Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity. J Biol Chem. 2015 May 08; 290(19):12058-67. PMID: 25802336.
      Citations:    
    22. Wang L, Burmeister BT, Johnson KR, Baillie GS, Karginov AV, Skidgel RA, O'Bryan JP, Carnegie GK. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy. Cell Signal. 2015 May; 27(5):908-22. PMID: 25683917.
      Citations:    
    23. Russo A, Okur MN, Bosland M, O'Bryan JP. Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2ß) isoform contributes to neuroblastoma tumorigenesis. Cancer Lett. 2015 Apr 10; 359(2):262-8. PMID: 25622909.
      Citations:    
    24. Okur MN, Russo A, O'Bryan JP. Receptor tyrosine kinase ubiquitylation involves the dynamic regulation of Cbl-Spry2 by intersectin 1 and the Shp2 tyrosine phosphatase. Mol Cell Biol. 2014 Jan; 34(2):271-9. PMID: 24216759.
      Citations:    
    25. Busciglio J, Capone G, O'Bryan J, O'Byran JP, Gardiner KJ. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits. Cytogenet Genome Res. 2013; 141(4):260-71. PMID: 24008277.
      Citations:    
    26. Hunter MP, Russo A, O'Bryan JP. Emerging roles for intersectin (ITSN) in regulating signaling and disease pathways. Int J Mol Sci. 2013 Apr 10; 14(4):7829-52. PMID: 23574942.
      Citations:    
    27. Wong KA, Russo A, Wang X, Chen YJ, Lavie A, O'Bryan JP. A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2ß) regulation. PLoS One. 2012; 7(9):e45360. PMID: 23028960.
      Citations:    
    28. Wong KA, Wilson J, Russo A, Wang L, Okur MN, Wang X, Martin NP, Scappini E, Carnegie GK, O'Bryan JP. Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks. PLoS One. 2012; 7(4):e36023. PMID: 22558309.
      Citations:    
    29. Russo A, O'Bryan JP. Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene. 2012 Nov 15; 31(46):4828-34. PMID: 22266851.
      Citations:    
    30. Elsherif L, Wang X, Grachoff M, Wolska BM, Geenen DL, O'Bryan JP. Cardiac-specific expression of the tetracycline transactivator confers increased heart function and survival following ischemia reperfusion injury. PLoS One. 2012; 7(1):e30129. PMID: 22272284.
      Citations:    
    31. Okur MN, Ooi J, Fong CW, Martinez N, Garcia-Dominguez C, Rojas JM, Guy G, O'Bryan JP. Intersectin 1 enhances Cbl ubiquitylation of epidermal growth factor receptor through regulation of Sprouty2-Cbl interaction. Mol Cell Biol. 2012 Feb; 32(4):817-25. PMID: 22158968.
      Citations:    
    32. Hunter MP, Nelson M, Kurzer M, Wang X, Kryscio RJ, Head E, Pinna G, O'Bryan JP. Intersectin 1 contributes to phenotypes in vivo: implications for Down's syndrome. Neuroreport. 2011 Oct 26; 22(15):767-72. PMID: 21876463.
      Citations:    
    33. Place AT, Chen Z, Bakhshi FR, Liu G, O'Bryan JP, Minshall RD. Cooperative role of caveolin-1 and C-terminal Src kinase binding protein in C-terminal Src kinase-mediated negative regulation of c-Src. Mol Pharmacol. 2011 Oct; 80(4):665-72. PMID: 21778303.
      Citations:    
    34. Wong KA, O'Bryan JP. Bimolecular fluorescence complementation. J Vis Exp. 2011 Apr 15; (50). PMID: 21525844.
      Citations:    
    35. O'Bryan JP. Intersecting pathways in cell biology. Sci Signal. 2010 Dec 14; 3(152):re10. PMID: 21156937.
      Citations:    
    36. Uchiki T, Kim HT, Zhai B, Gygi SP, Johnston JA, O'Bryan JP, Goldberg AL. The ubiquitin-interacting motif protein, S5a, is ubiquitinated by all types of ubiquitin ligases by a mechanism different from typical substrate recognition. J Biol Chem. 2009 May 08; 284(19):12622-32. PMID: 19240029.
      Citations:    
    37. Das M, Scappini E, Martin NP, Wong KA, Dunn S, Chen YJ, Miller SL, Domin J, O'Bryan JP. Regulation of neuron survival through an intersectin-phosphoinositide 3'-kinase C2beta-AKT pathway. Mol Cell Biol. 2007 Nov; 27(22):7906-17. PMID: 17875942.
      Citations:    
    38. Scappini E, Koh TW, Martin NP, O'Bryan JP. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase. Hum Mol Genet. 2007 Aug 01; 16(15):1862-71. PMID: 17550941.
      Citations:    
    39. Miller SLH, Scappini EL, O'Bryan J. Ubiquitin-interacting motifs inhibit aggregation of polyQ-expanded huntingtin. J Biol Chem. 2007 Mar 30; 282(13):10096-10103. PMID: 17276991.
      Citations:    
    40. Martin NP, Mohney RP, Dunn S, Das M, Scappini E, O'Bryan JP. Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling. Mol Pharmacol. 2006 Nov; 70(5):1643-53. PMID: 16914641.
      Citations:    
    41. Timsit YE, Miller SL, Mohney RP, O'Bryan JP. The U-box ligase carboxyl-terminus of Hsc 70-interacting protein ubiquitylates Epsin. Biochem Biophys Res Commun. 2005 Mar 11; 328(2):550-9. PMID: 15694383.
      Citations:    
    42. Miller SL, Malotky E, O'Bryan JP. Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation. J Biol Chem. 2004 Aug 06; 279(32):33528-37. PMID: 15155768.
      Citations:    
    43. Richman RW, Tombler E, Lau KK, Anantharam A, Rodriguez J, O'Bryan JP, Diversé-Pierluissi MA. N-type Ca2+ channels as scaffold proteins in the assembly of signaling molecules for GABAB receptor effects. J Biol Chem. 2004 Jun 04; 279(23):24649-58. PMID: 15047708.
      Citations:    
    44. Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 2004 Feb 15; 64(4):1266-77. PMID: 14973077.
      Citations:    
    45. Mohney RP, Das M, Bivona TG, Hanes R, Adams AG, Philips MR, O'Bryan JP. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. J Biol Chem. 2003 Nov 21; 278(47):47038-45. PMID: 12970366.
      Citations:    
    46. Oldham CE, Mohney RP, Miller SL, Hanes RN, O'Bryan JP. The ubiquitin-interacting motifs target the endocytic adaptor protein epsin for ubiquitination. Curr Biol. 2002 Jul 09; 12(13):1112-6. PMID: 12121618.
      Citations:    
    47. Storey NM, O'Bryan JP, Armstrong DL. Rac and Rho mediate opposing hormonal regulation of the ether-a-go-go-related potassium channel. Curr Biol. 2002 Jan 08; 12(1):27-33. PMID: 11790300.
      Citations:    
    48. O'Bryan JP, Mohney RP, Oldham CE. Mitogenesis and endocytosis: What's at the INTERSECTIoN? Oncogene. 2001 Oct 01; 20(44):6300-8. PMID: 11607832.
      Citations:    
    49. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001 Jul; 1(1):63-72. PMID: 11703924.
      Citations:    
    50. O'Bryan JP. Determining involvement of Shc proteins in signaling pathways. Methods Enzymol. 2001; 333:3-15. PMID: 11400346.
      Citations:    
    51. Sakai R, Henderson JT, O'Bryan JP, Elia AJ, Saxton TM, Pawson T. The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons. Neuron. 2000 Dec; 28(3):819-33. PMID: 11163269.
      Citations:    
    52. Tong XK, Hussain NK, Adams AG, O'Bryan JP, McPherson PS. Intersectin can regulate the Ras/MAP kinase pathway independent of its role in endocytosis. J Biol Chem. 2000 Sep 22; 275(38):29894-9. PMID: 10896662.
      Citations:    
    53. Adams A, Thorn JM, Yamabhai M, Kay BK, O'Bryan JP. Intersectin, an adaptor protein involved in clathrin-mediated endocytosis, activates mitogenic signaling pathways. J Biol Chem. 2000 Sep 01; 275(35):27414-20. PMID: 10851244.
      Citations:    
    54. Abe K, Whitehead IP, O'Bryan JP, Der CJ. Involvement of NH(2)-terminal sequences in the negative regulation of Vav signaling and transforming activity. J Biol Chem. 1999 Oct 22; 274(43):30410-8. PMID: 10521418.
      Citations:    
    55. O'Bryan JP. The PTB domain: a modular domain with multiple function. Curr Opin Drug Discov Devel. 1999 Sep; 2(5):505-18. PMID: 19649978.
      Citations:    
    56. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 28692342.
      Citations:    
    57. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 30366101.
      Citations:    
    58. Hussain NK, Yamabhai M, Ramjaun AR, Guy AM, Baranes D, O'Bryan JP, Der CJ, Kay BK, McPherson PS. Splice variants of intersectin are components of the endocytic machinery in neurons and nonneuronal cells. J Biol Chem. 1999 May 28; 274(22):15671-7. PMID: 10336464.
      Citations:    
    59. O'Bryan JP, Lambert QT, Der CJ. The src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor. J Biol Chem. 1998 Aug 07; 273(32):20431-7. PMID: 9685397.
      Citations:    
    60. Ganju P, O'Bryan JP, Der C, Winter J, James IF. Differential regulation of SHC proteins by nerve growth factor in sensory neurons and PC12 cells. Eur J Neurosci. 1998 Jun; 10(6):1995-2008. PMID: 9753087.
      Citations:    
    61. Biscardi JS, Denhez F, Buehler GF, Chesnutt DA, Baragona SC, O'Bryan JP, Der CJ, Fiordalisi JJ, Fults DW, Maness PF. Rek, a gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl/Tyro3 family. J Biol Chem. 1996 Nov 15; 271(46):29049-59. PMID: 8910558.
      Citations:    
    62. O'Bryan JP, Martin CB, Songyang Z, Cantley LC, Der CJ. Binding specificity and mutational analysis of the phosphotyrosine binding domain of the brain-specific adaptor protein ShcC. J Biol Chem. 1996 May 17; 271(20):11787-91. PMID: 8662772.
      Citations:    
    63. O'Bryan JP, Songyang Z, Cantley L, Der CJ, Pawson T. A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. Proc Natl Acad Sci U S A. 1996 Apr 02; 93(7):2729-34. PMID: 8610109.
      Citations:    
    64. O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem. 1995 Jan 13; 270(2):551-7. PMID: 7822279.
      Citations:    
    65. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood. 1994 Sep 15; 84(6):1931-41. PMID: 7521695.
      Citations:    
    66. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R, Le Beau MM, Earp HS, Liu ET. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991 Oct; 11(10):5016-31. PMID: 1656220.
      Citations:    
    67. Chen L, O'Bryan JP, Smith HS, Liu E. Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization. Oncogene. 1990 Sep; 5(9):1391-5. PMID: 2216462.
      Citations:    
    O'Bryan's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (389)
    Explore
    _
    Co-Authors (13)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _